AngioDynamics Sees MedTech Becoming Majority of Revenue in Fiscal 2027
AngioDynamics (NASDAQ:ANGO) said MedTech is expected to become a majority of revenue by fiscal 2027, citing Auryon share gains and ongoing AMBITION BTK enrollment. Management expects no Auryon study data in fiscal 2027, discussed possible coronary use, and guided fiscal 2027 gross margin to 54% to 55% and adjusted EBITDA to $13M to $16M.
How this was made
The 30-second read
Why it matters
The key tradable elements are fiscal 2027 margin and EBITDA guidance, a favorable Medicare local coverage determination for NanoKnife, and operational initiatives (sales leadership change, manufacturing transfer) that could support execution. Offsetting risks are explicit lack of AMBITION BTK data in fiscal 2027 and no FDA timing target for a potential coronary indication.
Market read
Traders can use the fiscal 2027 margin and adjusted EBITDA ranges plus the NanoKnife reimbursement update as near-term valuation anchors, while monitoring trial and FDA timing for upside realization.
What to watch
Tariff impact is still a headwind (about $5M prior year, with refunds excluded from guidance), and the article does not quantify how much the new sales leadership and manufacturing transfer will translate into near-term revenue acceleration.
Background
AngioDynamics is positioning its Auryon (below-the-knee vascular intervention), AlphaVac/AngioVac (thrombectomy and right-heart/infective endocarditis), and NanoKnife (interventional oncology) platforms to drive a higher MedTech revenue mix.
Ticker impact
AngioDynamics guided fiscal 2027 gross margin to 54% to 55% and adjusted EBITDA to $13M to $16M, plus discussed MedTech mix shift.
Likely modest positive bias for the stock as traders price in margin expansion and reimbursement momentum, with volatility around trial and regulatory timelines.
The article provides specific fiscal 2027 margin and EBITDA ranges, a favorable Palmetto GBA coverage determination effective July 5, and operational changes (sales leadership, manufacturing transfer), but it explicitly says investors should not expect AMBITION BTK data in fiscal 2027 and provides no FDA timing target.
Market effects
Reimbursement progress for interventional oncology and vascular devices can improve sentiment for medtech peers with similar coverage pathways.
Manufacturing labor shift to Costa Rica may be watched by investors for cost and supply-chain resilience in device manufacturing.
International expansion of the AMBITION BTK study may reinforce demand outside the US, but no specific geography or milestones are provided.
Counterpoint
The guidance may be optimistic if clinical timelines slip, since AMBITION BTK data is not expected in fiscal 2027 and the coronary application requires a multi-year FDA pathway.
Key entities
- companyAngioDynamics
Medical device maker guiding fiscal 2027 margins/EBITDA and updating clinical, reimbursement, and operational plans across its MedTech platforms.
- productAuryon
Peripheral vascular intervention device; management discussed share gains, above/below-the-knee procedure mix, and AMBITION BTK enrollment status.
- productNanoKnife
Interventional oncology platform; management cited 64% fiscal Q4 growth and a favorable Palmetto GBA local coverage determination effective July 5.
- productAlphaVac
Mechanical thrombectomy platform; management cited 44% fiscal 2026 growth and discussed APEX-Return study for pulmonary embolism.
- regulatorPalmetto GBA
Medicare Administrative Contractor that issued a favorable local coverage determination for NanoKnife in prostate and liver applications.
